CRXM: AI 评分 44/100 — AI 分析 (4月 2026)

Gene Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing angiogenic gene therapies for cardiovascular diseases. Its lead product, Generx, is currently in Phase 3 trials, targeting myocardial ischemia and refractory angina.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Gene Biotherapeutics, Inc. specializes in innovative angiogenic gene therapy biotherapeutics, with its lead candidate Generx in advanced clinical trials aimed at addressing significant cardiovascular health challenges.

CRXM是做什么的？

Gene Biotherapeutics, Inc., founded in 2003 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to developing and commercializing angiogenic gene therapy biotherapeutics specifically for treating cardiovascular diseases. The company was originally established as Taxus Cardium Pharmaceuticals Group, Inc. and rebranded to its current name in January 2018 to better reflect its focus on gene therapy. Gene Biotherapeutics is pioneering the use of its lead product candidate, Generx, which is currently undergoing Phase 3 clinical trials. Generx aims to treat patients suffering from myocardial ischemia and refractory angina, conditions that arise from advanced coronary artery disease. In addition to its primary indication, the company is exploring Generx for ischemia-related cardiovascular and cerebral therapeutic applications. To support its clinical evaluation efforts, Gene Biotherapeutics has partnered with Fujifilm Diosynth Biotechnologies for the manufacturing of Generx. This strategic collaboration is crucial as it ensures the production of high-quality biotherapeutics necessary for Phase 3 trials, which are pivotal for regulatory approval and subsequent commercialization. As a small company with only three employees, Gene Biotherapeutics is positioned in a niche segment of the biotechnology industry, focusing on innovative treatments that address unmet medical needs in cardiovascular health.

CRXM的投资论点是什么？

Gene Biotherapeutics, Inc. presents a unique investment thesis centered around its lead product candidate, Generx, which is currently in Phase 3 clinical trials. The successful completion of these trials could significantly enhance the company’s valuation, given the high unmet need for effective treatments for myocardial ischemia and refractory angina. The global market for cardiovascular gene therapies is projected to grow substantially, driven by increasing incidences of heart diseases and advancements in gene therapy technologies. Additionally, the partnership with Fujifilm Diosynth Biotechnologies not only bolsters manufacturing capabilities but also mitigates production risks, positioning the company favorably for potential commercialization. However, investors should remain cognizant of the inherent risks associated with clinical trials, including regulatory hurdles and market competition from established players in the biotechnology sector. Overall, Gene Biotherapeutics' focused approach on angiogenic therapies and its strategic partnerships are key value drivers that could lead to significant growth in the coming years.

CRXM在哪个行业运营？

The biotechnology industry, particularly in the healthcare sector, is experiencing rapid growth driven by advancements in gene therapy and personalized medicine. The global market for gene therapy is expected to reach $13.3 billion by 2026, with a compound annual growth rate (CAGR) of 30.5%. Gene Biotherapeutics, Inc. operates within this expanding market, focusing on innovative solutions for cardiovascular diseases, which remain a leading cause of mortality worldwide. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, all vying for a share of the lucrative cardiovascular treatment market. Gene Biotherapeutics' specialized focus on angiogenic therapies positions it uniquely among competitors, potentially allowing it to carve out a niche in this dynamic industry.

Biotechnology

Healthcare

CRXM有哪些增长机遇？

Expansion into ischemia-related therapeutic areas: Gene Biotherapeutics is exploring the use of Generx for additional ischemia-related cardiovascular and cerebral indications. The global market for ischemic heart disease therapies is projected to grow to $10 billion by 2027, providing substantial growth potential for the company as it diversifies its product applications.
Strategic partnerships for clinical development: Collaborating with established biotech firms and research institutions could enhance Gene Biotherapeutics' clinical development capabilities. Such partnerships may facilitate access to additional funding, expertise, and resources, accelerating the development timeline for Generx and future product candidates.
Regulatory approvals and market entry: Successful completion of Phase 3 trials and subsequent FDA approval could lead to commercialization of Generx, tapping into a market with significant unmet needs. The U.S. cardiovascular market is expected to reach $200 billion by 2025, positioning Gene Biotherapeutics to capture a share of this lucrative segment.
Technological advancements in gene therapy: As the biotechnology field rapidly evolves, Gene Biotherapeutics can leverage new technologies to enhance the efficacy and delivery of its gene therapies. Innovations in delivery mechanisms and genetic engineering could improve patient outcomes and broaden the applicability of Generx.
Geographic expansion into international markets: Once Generx achieves regulatory approval in the U.S., Gene Biotherapeutics may explore opportunities in international markets, particularly in regions with high cardiovascular disease prevalence. Expanding into Europe and Asia could significantly increase the company's market reach and revenue potential.

Lead product candidate Generx is in Phase 3 clinical trials, targeting myocardial ischemia.
Partnership with Fujifilm Diosynth Biotechnologies for manufacturing support.
Company rebranded from Taxus Cardium Pharmaceuticals Group in January 2018.
Market cap currently stands at $0.00B, indicating a pre-revenue stage.
High beta of 19.29 suggests significant volatility in stock performance.

CRXM提供哪些产品和服务？

Develops angiogenic gene therapy biotherapeutics for cardiovascular diseases.
Focuses on the treatment of myocardial ischemia and refractory angina.
Conducts Phase 3 clinical trials for its lead product candidate, Generx.
Collaborates with Fujifilm Diosynth Biotechnologies for manufacturing.
Explores additional therapeutic indications for Generx in ischemia-related conditions.
Operates as a clinical-stage biotechnology company with a small team.

CRXM如何赚钱？

Generates potential revenue through the commercialization of its lead product, Generx.
Engages in clinical trials to validate the efficacy and safety of its therapies.
Partners with manufacturing firms to ensure production capabilities for clinical evaluations.
Plans to expand into additional therapeutic areas to diversify revenue streams.
Aims to leverage partnerships for funding and resource sharing in drug development.

Patients suffering from cardiovascular diseases, particularly myocardial ischemia.
Healthcare providers seeking innovative treatment options for heart conditions.
Research institutions interested in gene therapy advancements.
Pharmaceutical companies for potential collaborations and partnerships.
Investors looking for opportunities in the biotechnology sector.

Specialization in angiogenic gene therapy, addressing a niche market.
Strong partnership with Fujifilm Diosynth Biotechnologies for manufacturing.
Focused research on unmet medical needs in cardiovascular health.
Innovative approach to gene therapy with potential for high patient impact.
Small team allows for agile decision-making and strategic pivots.

什么因素可能推动CRXM股价上涨？

Upcoming: Completion of Phase 3 clinical trials for Generx could lead to significant valuation increases.
Ongoing: Collaboration with Fujifilm Diosynth Biotechnologies for manufacturing support.
Upcoming: Potential FDA submission for Generx following successful trial outcomes.
Ongoing: Exploration of additional therapeutic indications for Generx.
Upcoming: Strategic partnerships to enhance clinical development capabilities.

CRXM的主要风险是什么？

Ongoing: High competition from established biotechnology and pharmaceutical companies.
Potential: Regulatory hurdles could delay the approval process for Generx.
Ongoing: Dependence on successful clinical trial outcomes for future growth.
Potential: Market volatility affecting investor sentiment and funding opportunities.
Ongoing: Limited financial resources could restrict operational capacity.

CRXM的核心优势是什么？

Innovative focus on angiogenic gene therapies for cardiovascular diseases.
Partnership with a reputable manufacturing firm enhances production capabilities.
Strong potential market for cardiovascular treatments due to high disease prevalence.

CRXM的劣势是什么？

Limited financial resources as indicated by a market cap of $0.00B.
Small team size may restrict operational capacity and scalability.
Dependence on successful clinical trial outcomes for future growth.

CRXM有哪些机遇？

Expanding therapeutic applications for Generx could capture additional market segments.
Potential for international market entry post-FDA approval.
Technological advancements in gene therapy could improve product efficacy.

CRXM面临哪些威胁？

High competition from established pharmaceutical and biotechnology companies.
Regulatory hurdles in the approval process for new therapies.
Market volatility and investor sentiment affecting funding opportunities.

CRXM的竞争对手是谁？

AccuStem Sciences, Inc. — Focuses on precision medicine in oncology. — (ACCA)
Cryoport, Inc. — Provides logistics solutions for cell and gene therapies. — (CRYO)
Equillium, Inc. — Develops therapies for severe autoimmune diseases. — (EQUR)
FSD Pharma Inc. — Works on cannabinoid-based therapies. — (FPSUF)
GlycoMimetics, Inc. — Focuses on glycobiology for cancer and rare diseases. — (GLSHQ)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Christopher J. Reinhard
Headquarters: San Diego, US
Employees: 3
Founded: 2000

AI Insight

AI analysis pending for CRXM

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Gene Biotherapeutics, Inc. do?

Gene Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing angiogenic gene therapies for cardiovascular diseases. Its lead product candidate, Generx, is currently in Phase 3 clinical trials, targeting conditions such as myocardial ischemia and refractory angina. The company aims to address significant unmet medical needs in the cardiovascular space through innovative gene therapy solutions.

What do analysts say about CRXM stock?

Analyst consensus on CRXM stock highlights the potential of Generx, particularly if Phase 3 trials yield positive results. Key valuation metrics indicate a pre-revenue stage, and analysts are closely monitoring the company's progress in clinical trials and regulatory submissions. The biotechnology sector's growth prospects add to the interest in CRXM, although the stock remains speculative due to its current stage.

What are the main risks for CRXM?

Gene Biotherapeutics, Inc. faces several risks, including high competition from established players in the biotechnology sector, which may impact its market share. Regulatory hurdles pose a significant risk, as delays in the approval process for Generx could hinder commercialization efforts. Additionally, the company's reliance on successful clinical trial outcomes and limited financial resources could restrict its growth and operational capacity.